PORT WASHINGTON, N.Y. (September 1, 2021)—Drive DeVilbiss Healthcare announced today the discontinuation of the DV5 and DV6 series CPAP devices as of December 2021. As a result, Drive DeVilbiss will no longer accept new CPAP orders in order to fill as many open orders as possible.
The decision to discontinue the CPAP line comes from raw material shortages, difficulty securing needed parts and increased component pricing. Drive DeVilbiss will continue to focus on its market-leading oxygen products in response to the pandemic.
“Over the last two years, Drive DeVilbiss has been a major supplier of critical oxygen products during the largest respiratory pandemic in history,” said Derek Lampert, CEO. “It has been our duty to provide essential therapeutic oxygen products to the global market. We have taken that responsibility very seriously and have focused our resources to that end. With the most recent resurgence of COVID-19, we continue to run at maximum capacity. The ability to transition the manufacturing space away from the CPAP lines will allow us to raise our output of these critical medical devices.”
For over 30 years, Drive DeVilbiss Healthcare has been an important contributor to the sleep market. Its first CPAP was launched in 1989, followed by one of the first commercially available auto-adjusting CPAPs in 1995. Five years later, remote monitoring was introduced.
Drive DeVilbiss will continue to support warranty commitments on the DV5 and DV6 Series CPAP products and the sale of accessories such as chambers, filters and patient tubing, to support continued usage of the CPAPs by users.
Visit drivemedical.com for more information.
